- Home
- FGEN vs ANTX Comparison
FGEN vs ANTX Comparison
Compare FGEN & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FGEN
- ANTX
- Stock Information
- Founded
- FGEN 1993
- ANTX 2017
- Country
- FGEN United States
- ANTX United States
- Employees
- FGEN N/A
- ANTX N/A
- Industry
- FGEN Biotechnology: Pharmaceutical Preparations
- ANTX Biotechnology: Pharmaceutical Preparations
- Sector
- FGEN Health Care
- ANTX Health Care
- Exchange
- FGEN Nasdaq
- ANTX Nasdaq
- Market Cap
- FGEN 33.5M
- ANTX 33.2M
- IPO Year
- FGEN 2014
- ANTX 2022
- Fundamental
- Price
- FGEN $7.45
- ANTX $1.10
- Analyst Decision
- FGEN Strong Buy
- ANTX Buy
- Analyst Count
- FGEN 1
- ANTX 2
- Target Price
- FGEN $250.00
- ANTX $2.00
- AVG Volume (30 Days)
- FGEN 48.5K
- ANTX 71.5K
- Earning Date
- FGEN 08-05-2025
- ANTX 08-12-2025
- Dividend Yield
- FGEN N/A
- ANTX N/A
- EPS Growth
- FGEN N/A
- ANTX N/A
- EPS
- FGEN N/A
- ANTX N/A
- Revenue
- FGEN $6,996,000.00
- ANTX N/A
- Revenue This Year
- FGEN N/A
- ANTX N/A
- Revenue Next Year
- FGEN N/A
- ANTX N/A
- P/E Ratio
- FGEN N/A
- ANTX N/A
- Revenue Growth
- FGEN N/A
- ANTX N/A
- 52 Week Low
- FGEN $4.50
- ANTX $0.87
- 52 Week High
- FGEN $33.49
- ANTX $2.73
- Technical
- Relative Strength Index (RSI)
- FGEN 55.79
- ANTX 50.52
- Support Level
- FGEN $7.31
- ANTX $1.05
- Resistance Level
- FGEN $7.82
- ANTX $1.16
- Average True Range (ATR)
- FGEN 0.59
- ANTX 0.03
- MACD
- FGEN 0.10
- ANTX 0.01
- Stochastic Oscillator
- FGEN 69.35
- ANTX 47.17
About FGEN FibroGen Inc
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.